Navigation Links
HIV Takes Advantage of Rivalry among T cells

Houston: A novel HIV study has demonstrated how intense struggle among the human immune system's T cells gives the leeway to the virus to survive harm and take on a more virulent form, developing into the advanced stages of AIDS. // The study, which uses a computer model of simultaneous virus and immune system evolution, also gives a hint of a new strategy for using vaccines against the virus. The research, which is slated for publication in Physical Review Letters, is available online at http://arxiv.org/abs/q-bio.PE/0610018.

"Competition among T cells exerts a small influence for most diseases, but it's fatal for HIV," said study co-author Michael Deem, Rice University's John W. Cox Professor in Biochemical and Genetic Engineering and professor of physics and astronomy.

The new computer model, created by Deem and Guanyu Wang, now an assistant professor of physics at George Washington University, is the first to accurately reproduce all three stages of HIV infection. The first is marked by an initial spike in virus production that's immediately followed by dramatic drop as the immune system recognizes the threat, mounts a defense and destroys most of the invading viruses. The second phase is a long period of clinical latency that can last up to 10 years. In this phase, a small amount of virus mutates fast enough to escape initial detection and continues to mutate over time. The third phase, AIDS, occurs when the virus has changed so much that the body's T cells are no longer effective at keeping it in check.

Deem and Wang's computer model accurately describes all three phases of HIV infection by incorporating a key component: competition among T cells. The model includes two forms of competition. The first form leads to a phenomenon known as deceptive imprinting, or original antigenic sin. Original antigenic sin is the tendency for memory immune cells produced in response to a first viral infection to suppress the creation of new immun e cells in response to a second infection by a related strain. The second type of competition, immunodominance, occurs when several viral strains simultaneously infect one person. In this case, T cells compete to recognize the different strains. The winners – the T cells that the body produces in mass quantities to fight the disease – are the ones with the best overall record against the most recogniztable strains. Among the losers, however, there may be T cells that better control the other less recognizable, but still deadly, strains.

"Once the immune system chooses a winning set of T cells, it has a natural tendency to go with those cells when it's confronted by new strains of the same disease in the future," Deem said. "For HIV, which mutates rapidly, this is an Achilles' heel. We found a direct correlation between the level of competition among T cells and the rate at which the virus escaped."

Deem said one strategy to combat this effect would be to vaccinate against the strains of HIV that will inevitably evolve in the body in a manner that was designed to reduce immunodominance. One such strategy – polytopic vaccination – involves giving vaccines against different strains of the same disease simultaneously in different parts of the body. The approach capitalizes on the fact that different lymph nodes – the sites where T cells compete to be chosen as the winners against a particular disease – act as collection points for different parts of the body. Moreover, because it takes 4-5 days for T cells produced in a lymph node to begin to leave it, the possibility exists to set up simultaneous, independent competition against each of the multiple strains that will evolve by injecting each strain simultaneously so that they drain to different lymph nodes. In this case, no single T cell is chosen as a winner. Instead, a separate winner for each strain is picked in each affected lymph node before immunodominance can come into play.

"In our si mulations, this strategy appears effective at all but eliminating competition among T cells," Deem said. "As a result, HIV remained in a state of permanent latency and was never able to escape the immune system's grasp to develop into AIDS."



Source-EurekalertSAV
'"/>




Related medicine news :

1. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
2. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
3. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
4. Bhitarkanika Sanctuary In Orissa Takes Precaution To Monitor Bird Flu
5. Government Takes Tough Stand Against Falling Sex Ratio
6. Bill Gates Takes Personal Interest in AIDS Program
7. Wake Up Call: U.N Takes Stock to Curb Fake Medicines Racket
8. 37 times unlucky – Failure to Diagnose Cancer, Takes the Life of a 31 year old fathe
9. So (y) Good: Soy Meal Takes-Off After Bird-Flu Crisis
10. Government Takes Steps to Reduce Binge Drinking Among Britons
11. Its High Time the Australian Government Takes Steps against Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance and ... to clients in southern Montana, is announcing a focused charity effort to gather ... outreach programs offered by Zoo Montana provide students with current knowledge on the ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with the ... for families with children receiving treatment in nearby hospitals. , Ronald McDonald House ...
(Date:6/27/2017)... , ... June 27, 2017 , ... DrugDev ... is whether they can trust the sponsor to pay them correctly and on time. ... and CROs establish payment strategies that encourage sites to work on their studies. , ...
(Date:6/27/2017)... MA (PRWEB) , ... June 27, 2017 , ... The ... Senate bill to repeal and replace the 2010 Patient Protection and Affordable Care Act ... compared with what would be expected under current law. , More than 20 million ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article on medGadget ... $6.81 billion by the year 2024 according to a new report. The article also ... made from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... 7, 2017 Endo International plc (NASDAQ: ... the Hon. Joseph R. Goodwin , U.S. District ... West Virginia , entered a case management order ... System Products Liability Litigation (the "MDL") that includes a ... provide expert disclosures on specific causation within one hundred ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: